FierceBiotech Sits Down With H1

Biopharma companies don't want to go to market with a product no one knows about. H1 has homed in on the often time-consuming research and engagement phases that companies must ace for a successful launch, said Ariel Katz, co-founder of H1.

Katz recently sat down with FierceBiotech Publisher Rebecca Willumson to discuss challenges and solutions in the space, as well as a newly launched social listening tool that brings even more data to H1’s offering.

For more from Katz, watch the video.

FierceBiotech Sits Down With Accenture

Kevin Julian, senior managing director of Accenture’s life sciences practice, recently sat down with FierceBiotech to discuss market trends and Accenture’s new technology platform, INTIENT. With the launch of the platform last year, Accenture brought to market a new generation of solutions for biopharmas. 

For more from Julian, watch the video.